We are live on ! Find out more
ONC icon

BeOne Medicines

205 hedge funds and large institutions have $7.27B invested in BeOne Medicines in 2024 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 88 increasing their positions, 45 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

108% more capital inflows, than outflows

Capital inflows: $439M | Capital outflows: $212M

96% more repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 45

29% more funds holding in top 10

Funds holding in top 10: 7 → 9 (+2)

1.32% more ownership

Funds ownership: 43.18% → 44.5% (+1.3%)

8% more call options, than puts

Call options by funds: $14.2M | Put options by funds: $13.2M

0% more funds holding

Funds holding: 204 → 205 (+1)

6% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 35

Holders
205
Holders Change
+1
Holders Change %
+0.49%
% of All Funds
2.94%
Holding in Top 10
9
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+28.57%
% of All Funds
0.13%
New
33
Increased
88
Reduced
45
Closed
35
Calls
$14.2​M
Puts
$13.2​M
Net Calls
+$1.03​M
Net Calls Change
+$365​K

ONC Hedge Fund Activity: Q1 2024 in Review

205 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines (ONC) for Q1 2024, worth a combined $7.27B — down 10% from $8.11B a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of ONC and 33 opened new positions — a net loss of 2 holders — while 45 trimmed existing stakes and 88 added.

The largest buyer was Capital International Investors, adding an estimated $117M. The largest seller was Invesco, cutting an estimated $43.4M.

  • 205 institutional investors held BeOne Medicines (ONC) as of Q1 2024, up from 204 in Q4 2023.
  • Funds reported $7.27B of BeOne Medicines stock for Q1 2024, down 10% quarter-over-quarter.
  • 33 funds opened new BeOne Medicines positions in Q1 2024 and 35 closed out, a net change of -2 holders.
  • The largest BeOne Medicines buyer in Q1 2024 was Capital International Investors, an estimated $117M added.
  • The largest BeOne Medicines seller in Q1 2024 was Invesco, an estimated $43.4M sold.

Based on aggregated 13F filings for Q1 2024.